Inventor · disambiguated record
Kurt R. Brunden
Also filed as: BRUNDEN KURT R
12 granted patents·15 pending applications·80 citations·filing 1998–2024
86Inventor score
Top patents by PatentIndex Score
27 records- 0186US6333034B1Process for inhibiting complement activation via the alternative pathwayGLIATECH INC·Filed 1998·Granted Dec 25, 2001·71 cites·14 claims
- 0283US11155608B2Monoclonal antibodies against pathological alpha-synuclein, and methods using sameUNIV PENNSYLVANIA·Filed 2018·Granted Oct 26, 2021·2 cites·18 claims
- 0381US2025136670A1Monoclonal Antibodies Against Alpha-Synuclein FibrilsUNIV PENNSYLVANIA·Filed 2024·Application pending·0 cites
- 0480US9649317B2Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathiesUNIV PENNSYLVANIA·Filed 2013·Granted May 16, 2017·2 cites·32 claims
- 0574US12071474B2Monoclonal antibodies against alpha-synuclein fibrilsUNIV PENNSYLVANIA·Filed 2022·Granted Aug 27, 2024·0 cites·7 claims
- 0666US2022041698A1Monoclonal Antibodies Against Pathological Alpha-Synuclein, and Methods Using SameUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 0765US11220538B2Monoclonal antibodies against alpha-synuclein fibrilsUNIV PENNSYLVANIA·Filed 2018·Granted Jan 11, 2022·0 cites·23 claims
- 0863US6946474B2Nitrogen-containing compounds and their use as glycine transport inhibitorsMERCK & CO INC·Filed 2001·Granted Sep 20, 2005·2 cites·4 claims
- 0960US9643919B2Cycloalkyl-dione derivatives and methods of their useUNIV PENNSYLVANIA·Filed 2014·Granted May 9, 2017·0 cites·30 claims
- 1055US8927586B2Thromboxane A2 (TP) receptor antagonistsUNIV PENNSYLVANIA·Filed 2013·Granted Jan 6, 2015·0 cites·2 claims
- 1153US2017173016A1Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathiesUNIV PENNSYLVANIA·Filed 2017·Application pending·0 cites
- 1253US2023167121A1Substituted {1,2,4,} triazolo{1,5-a} pyrimidine compounds and use in stabilizing microtubulesUNIV PENNSYLVANIA·Filed 2021·Application pending·0 cites
- 1351US11623927B2Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubulesUNIV PENNSYLVANIA·Filed 2019·Granted Apr 11, 2023·0 cites·18 claims
- 1450US2013190370A1Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) ReceptorTROJANOWSKI JOHN Q·Filed 2011·Application pending·0 cites
- 1549US2023025707A1Anti-Alpha-Synuclein Monoclonal Antibodies, and Methods Using SameUNIV PENNSYLVANIA·Filed 2020·Application pending·0 cites
- 1647US2003198636A1Process for inhibiting complement activation via the alternative pathwayFiled 2003·Application pending·0 cites
- 1746US2022227772A1Deuterated triazolopyrimidinesUNIV PENNSYLVANIA·Filed 2020·Application pending·0 cites
- 1845US2003069295A1Use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesityGLIATECH INC·Filed 2001·Application pending·0 cites
- 1944US2002015701A1Process for inhibiting complement activation via the alternative pathwayFiled 2001·Application pending·0 cites
- 2042US2003165907A1Human glycine transporter type 2GLIATECH INC·Filed 2002·Application pending·0 cites
- 2139US7049343B2Substituted hydrazine derivativesMERCK & CO INC·Filed 2001·Granted May 23, 2006·0 cites·5 claims
- 2239US2013337463A1Cell-Based Models of Neurodegenerative DiseaseBRUNDEN KURT R·Filed 2011·Application pending·0 cites
- 2338US2013029983A1Aminothienopyridazine inhibitors of tau assemblyBALLATORE CARLO·Filed 2010·Application pending·0 cites
- 2436US2004082018A1Methods for using osteocalcinATHERSYS INC·Filed 2002·Application pending·0 cites
- 2536US2004006120A1Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesityFiled 2001·Application pending·0 cites
- 2635US6416975B1Human glycine transporter type 2GLIATECH INC·Filed 1998·Granted Jul 9, 2002·3 cites·82 claims
- 2731US8530520B2Cycloalkyl-dione derivatives and methods of their useATASOYLU ONUR·Filed 2012·Granted Sep 10, 2013·0 cites·28 claims
Join the waitlist — get patent alerts
Get an alert when Kurt R. Brunden files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →